NECANN’s 4th Annual New Jersey Cannabis Convention Is The Perfect Setting to Learn Everything about the Cannabis Industry

The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized the sale of recreational marijuana, which led to the April 2023 opening of the first licensed recreational marijuana dispensary in Atlantic City (https://cnw.fm/KVDTv).

With such stores finally opening and the number of licenses rapidly increasing, the number of ancillary businesses, entrepreneurs, investors, cultivators, medical dispensaries, license holders, and suppliers, is increasing by the day. Conveniently, NECANN’s New Jersey Cannabis Convention is designed for this category of budding industry players and entrants, among others. The event represents everything that touches cannabis and promises to be the perfect setting for attendees to learn about the industry.

“There’s everything here that you could possibly learn about the cannabis industry. Everything from grow lights, payment processors, banking, [and] accounting. If you are looking to start any type of cannabis business, you can come to NECANN and learn whatever you are trying to learn,” said Brian O’Connor of Paybotic, a payment processor that enables cannabis businesses to transact, in a video recapping the 2021 event (https://cnw.fm/HJvmM).

What makes the New Jersey Cannabis Convention particularly appealing to startups is the fact that it is an opportunity to meet similar sprouting businesses. Even so, the event is equally suited for exhibitors drawn from every niche within the cannabis industry. Attracting thousands of cultivators, industry professionals, educators, and advocates, from hundreds of local and national companies, the New Jersey Cannabis Convention promises a lot of foot traffic, much to the advantage of vendors and businesses showcasing their products. In fact, exhibitors who were part of previous editions of the event have lauded its role in bringing them closer to investors and potential business partners. The 2023 event will be no different, so reserve your exhibit space today.

For attendees in pursuit of knowledge, there’s more! The activity-packed two-day event features learnings from expert speakers delivered through dozens of planned sessions. Moreover, there are plenty of networking opportunities. The New Jersey Cannabis Convention is the perfect setting to learn, meet, and network. So do not miss it – register today.

For more information, please visit https://cnw.fm/DiUCt

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Court Ruling Puts New York’s Cannabis Equity Program in Jeopardy

Efforts to launch an equitable recreational cannabis industry in New York hit another roadblock after a state Supreme Court judge ruled that the licensing process violated state law. The most recent state Supreme Court ruling has now deemed the licensing process for social equity applicants unconstitutional and banned the state Office of Cannabis Management from providing any new retail recreational cannabis licenses until Aug. 25, 2023, when there will be further arguments on the matter.

Like other states with recreational cannabis markets, New York sought to launch an industry that provided equitable access to victims of the failed drug war via social-equity processes such as getting the first crack at the state’s first batch of adult-use cannabis retail licenses. However, a group of disabled veterans looking to enter the nascent cannabis market challenged the preferential licensing process for social-equity applicants in a state Supreme Court lawsuit.

The veterans argued that the Office of Cannabis Management violated state law by only allowing individuals with cannabis-related offenses and their immediate family members to apply for cannabis licenses rather than opening the application process to everyone. This lawsuit came months after multistate cannabis operators with medical marijuana licenses sued New York regulators for shutting them out of the recreational cannabis industry.

Although the ruling by Supreme Court Judge Kevin Bryant will not apply to individuals who had met the licensing conditions before Aug. 7, 2023, it will likely impact the hundreds of business owners looking to apply for Conditional Adult Use Retail Dispensary (CAURD) licenses.

CAURD permits are the only existing licenses for legal recreational cannabis sales in New York, meaning cutting access to these licenses essentially prevents entrepreneurs from entering the cannabis industry.

State regulators may have had their hearts in the right place in terms of social equity when they implemented the selective licensing program, but it has had major repercussions for the state adult-use cannabis market. According to the lawsuit filed by the disabled veterans, the New York Office of Cannabis Management has failed in its mandate to create the marijuana market “envisioned by the Marihuana Regulation and Taxation Act (MRTA),” particularly by preventing disabled military veterans and other minorities from access cannabis licenses.

The suit argued that every day that New York’s recreational cannabis program was limited to CAURD program participants impacted priority groups included in the MRTA as well as New York State farmers.

A spokesperson from the OCM said the agency will appeal the recent state Supreme Court ruling.

If these hiccups to the full launch of the recreational marijuana market in New York State continue, many opportunities are likely to be lost by entrepreneurs, such as those operating ancillary businesses similar to Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Medical Cannabis Firm Sues DEA Over Unjustifiable Licensing Delays

A medical marijuana company that focuses on developing cannabis-derived pharmaceuticals has filed a suit against the U.S. Drug Enforcement Administration (DEA) over “exponential delays” in the agency’s licensing process for cultivating medical research cannabis. MMJ BioPharma Cultivation sued the DEA in the U.S. Court of Appeals for the DC Circuit, claiming that the DEA’s licensing process, which can take several years, has prevented innovation which could help patients and which hamper the company’s business.

The Rhode Island-based medical cannabis company asked the federal court to compel the DEA into action and hopefully streamline its licensing process. MMJ said in its suit that although it began the licensing process in late 2017, several years of licensing delays have kept it from carrying out the research it was meant to do. The company is currently working to develop gel capsules with marijuana extracts to treat Huntington’s disease and multiple sclerosis (MS).

The DEA allowed MMJ to import cannabis for research from Canada, but the medical cannabis company ran into a wall when it applied for a license to cultivate cannabis for research purposes in-house rather than obtain it from Canada. According to MMJ, granting the company in-house cultivation privileges is “essential” to its ability to run clinical trials on the efficacy of cannabis against various health conditions.

MMJ added that without the ability to grow cannabis in-house to its own specifications, the company cannot develop a proper compound.

Its petition notes that it began the preregistration process for license application in June 2021 and went through several steps before a DEA diversion investigator informed MMJ officials they needed to wait for a final determination from DEA Headquarters. The petition claims MMJ did not receive a final determination from the DEA despite numerous follow-up attempts.

Furthermore, DEA personnel told MMJ officials that the agency still hadn’t made the final determination and they had “no idea” when the DEA would make the determination. According to the court filing, DEA personnel responded to subsequent inquiries on the progress of the final determination with statements such as, “Why do you want to know?” and “We’ll get to it when we get to it.”

MMJ states that the DEA still hasn’t made a final determination on its in-house cannabis cultivation license for research purposes for “some inexplicable reason,” even though the agency granted it a research license.

Company president Duane Boise argued in a press release that the DEA had failed its legislative mandate and pledged to get to the bottom of the issue.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — State Cannabis Regulators Urge Congress to Look Beyond CBD While Enacting Cannabinoid Regulations

State cannabis regulators are informing congressional legislators that, in addition to providing the FDA with more regulatory power, their investigation into the absence of federal regulations for CBD products derived from hemp must consider other cannabinoids that are becoming more widely available, such as delta-8 tetrahydrocannabinol.

Last Friday, the Cannabis Regulators Association (CANNRA) sent lawmakers a letter with proposals for developing a framework for all hemp-derived cannabinoids in reply to a request for expert advice on CBD laws from major Senate and House committees. The group members’ combined experience managing state cannabis initiatives served as the basis for the application.

While CBD has received a lot of attention, all derivatives other than delta-9 tetrahydrocannabinol, including psychoactive substances such as THC-O-acetate and delta-8 tetrahydrocannabinol, were also widely deregulated when hemp was legalized federally under the 2018 Farm Bill. CANNRA argued that Congress renamed marijuana as hemp and effectively legalized it on a federal level, with no restrictions on products.

Although the DEA has stated that it views cannabinoids as illegal if they are synthesized, which is typical for delta-8 tetrahydrocannabinol, the demand for these products has grown with little enforcement. Numerous states have acted on their own to outlaw or regulate them.

The FDA has been under fire from a number of legislators and hemp stakeholders for not enacting CBD regulations, but CANNRA stated that it concurs with the FDA that it does not currently have the jurisdiction to create the kind of complete framework required for a market this complicated. According to the regulators, the FDA requires precise authority and brief timeframes for issuing regulations.

Furthermore, the association recommended that the FDA work in tandem with tribes, territories and states to ensure that regulations are not created in isolation. And states ought to have the authority to pass laws that go above and beyond federal minimum requirements to better safeguard their citizens and businesses, even though federal regulations are crucial.

The letter also offers thorough answers to some 24 specific queries outlined by the committees on the matter. These questions covered a wide range of topics, from the state of the CBD market today to the difficulties associated with the lack of regulations to the specifications for labeling and packaging.

CANNRA is not the only group that has replied to the request for information. The United States Hemp Roundtable also addressed the panel’s inquiries in a letter. In contrast to CANNRA, the group contended that Congress ought to order the FDA to act, disputing its claim that it lacks the appropriate power to create a cannabinoids regulatory framework.

The ATACH also replied with a letter stating that, although the FDA ought to regulate CBD, unregulated synthetic hemp intoxicants are the real issue. The group argued that the TTB, not the FDA, ought to regulate these goods.

Cornbread Hemp, a CBD company based in Kentucky, also gave the committees its take on the matter. In its view, the absence of FDA regulations has created a fragmented collection of state regulations that adversely affect businesses and perplex consumers.

As these anticipated regulations are codified, the market for the products commercialized by enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) is likely to expand as more entities increase their cannabis production.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIH-Funded Research Finds Near Record-Level Use of Cannabis, Hallucinogens, Alcohol by Middle-Aged Adults

Research funded by the National Institutes of Health has revealed historic high levels of cannabis, hallucinogens and alcohol use among adults aged 35 to 50 years old. The NIH-funded study stated that the use of hallucinogens and marijuana by middle-aged adults, which has been on an upward trajectory for several years, peaked in 2022.

Furthermore, younger adults who also took part in the annual Monitoring the Future (MTF) panel study reported record high levels of hallucinogen, cannabis, and vape use. The report showed a significant increase in past-year hallucinogen and cannabis use as well as nicotine vaping in the past five years among adults aged 19 to 30 years old. This age group recorded its highest-ever level of cannabis use and vaping in 2022, the MTF study found.

The study was conducted by researchers from the Institute for Social Research at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA).

Cannabis reform has swept across America in the past two decades and left dozens of state medical and recreational cannabis programs in its wake. Tens of millions of Americans now have access to cannabis, and as lawmakers in several states work on legalizing psychedelics, access to hallucinogenics is steadily increasing.

The report indicated that many adults are turning to cannabis for its therapeutic properties while others have made the plant their social drug in place of alcohol and tobacco. Younger adults continued the trend of moving away from alcohol and exhibited reduced rates of binge drinking over the past decade. On the other hand, middle-aged adults aged 35 to 50 reported the highest binge drinking rates amid major past-year, five-year and 10-year increases in the prevalence of binge drinking.

Specifically, the report noted that 28% of middle-aged adults used cannabis in the past 12 months up from 25% in 2021, an all-time high and more than double the 13% who reported past-year cannabis use in 2012. Past-year psychedelic use in middle-aged adults was also at a record high at 4%, double the 2% in 2021, and substantially more than less than 1% in 2012 and 2017.

Middle-aged adults also reported record high rates of alcohol use. Past-year drinking was up to 85% in 2022 from 83% in 2012 and binge drinking increased to record levels at 29% in 2022 from 26% in 2021, 25% in 2017, and 24% in 2012.

NIDA director Nora Volkow noted that older adults take part in substance use just as much as teens and younger adults. The data collected in this year’s MTF panel study will help the agency better understand drug use trends across people’s lives, the director said, a crucial first step to understanding how substance use and its effects on health evolve over time. Volkow added that the agency wanted to equip younger to older adults with up-to-date information to help them make better-informed substance use-related decisions.

Psychedelics and marijuana are used by some people for medicinal reasons, and companies are looking to standardize therapeutic formulations from cannabis so that these medically oriented users of marijuana can safely address their symptoms while reducing the risks they face from the use of these substances.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — German Cabinet OKs Recreational Marijuana Legalization Plan

The German government approved a preliminary statute, marking a significant step toward legalizing recreational cannabis. Under the upcoming legislation, adults would be permitted to own a maximum of 25 grams (approximately 0.9 ounces) of marijuana and cultivate up to three plants for personal use. Moreover, they could participate in not-for-profit “marijuana clubs,” comprising up to 500 members, where the legal growth and purchase of the substance would be permissible.

The bill’s journey to becoming law is not yet complete. The legislation must be approved by German parliamentarians who are slated to reconvene on Sept. 4, 2023, after their summer recess.

Karl Lauterbach, the country’s health minister, hailed the draft legislation as a pivotal moment in Germany’s stance on marijuana. According to him, the more lenient approach holds the potential to combat the illicit market and drug-linked offenses. Moreover, it could alleviate the pressure on law-enforcement agencies and encourage safer cannabis consumption.

While this shift appears to endorse a more permissive attitude, minors would still be barred from cannabis use, with a planned government campaign alerting young people to the associated health hazards.

The new legislation, a centerpiece of Chancellor Olaf Scholz’s coalition, marks a departure from one of Europe’s most liberal marijuana policies. Nevertheless, the current draft has undergone modifications from its original, more ambitious, form. Notably, plans to permit the widespread commercial sale of cannabis through licensed outlets were jettisoned in April due to reservations raised by the European Commission.

Despite these changes, the draft law has faced formidable opposition from conservative politicians, medical professionals and law-enforcement representatives. A notable detractor is Klaus Holetschek, Bavaria’s regional health minister from the CDU party, who has branded the proposals as reckless. He argues that past examples from other nations reveal that liberalization does little to suppress the illegal market.

The German Professional Association of Pediatricians, in conjunction with other youth healthcare groups, has also criticized the plans for potentially encouraging cannabis use among young individuals. In addition, the law-enforcement community, including judges and police unions, has voiced concerns, characterizing the legislation as overly bureaucratic. They fear that the law could exacerbate the situation rather than alleviate burdens on the judicial system.

However, Lauterbach welcomes the controversial discourse initiated by the proposals, although he contends that critics fail to offer viable alternatives. Lauterbach staunchly advocates for a decriminalization approach, coupled with stringent restrictions and comprehensive education on the perils of cannabis consumption. To further regulate the use of cannabis, the legislation designates a 200-meter exclusion zone around cannabis clubs, sports facilities, playgrounds, youth organizations and schools.

If the bill garners approval, the government plans to assess its societal impact after a span of four years.

This initiative aligns with a global trend, as multiple countries have taken steps to relax regulations surrounding cannabis use. In 2013, Uruguay led the charge by legalizing the cultivation, sale and consumption of cannabis, setting a precedent for the world. In the United States, numerous states, including California, have progressively revised their laws over the last decade to accommodate recreational marijuana use.

Malta achieved a landmark feat in 2021 as the first European Union member to legalize recreational marijuana. Meanwhile, the Netherlands has long tolerated the sale and consumption of marijuana in designated “coffee shops” since the 1970s.

Drawing inspiration from these international examples, Lauterbach expresses confidence that the current form of the German plan constitutes the most comprehensive endeavor in marijuana legislation to date.

When this marijuana market finally opens, many companies that operate along the lines of U.S-based Advanced Container Technologies Inc. (OTC: ACTX) are likely to mushroom and strive as they serve those interested in growing their own marijuana at home.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Analysis Shows Ohio Stands to Collect $404M in Annual Cannabis Taxes

Ohio has the potential to witness a substantial boost in its yearly tax revenue, reaching an impressive $403.5 million from the sales of recreational marijuana, according to a fresh analysis by researchers at Ohio State University. The researchers base their tax revenue estimations on the initial years of sales, drawing insights from comparable markets in other states.

The study primarily hones in on the patterns of cannabis sales in Michigan, a neighboring state with a similar population size. Additionally, Michigan’s tax structure bears a striking resemblance to the one that Ohio would likely adopt if the legalization measure gets the nod. The research also casts its gaze on sales figures from 2018 to 2023 in states such as Washington, Oregon, Nevada, Illinois, and Colorado.

This report marks the second iteration, an update from last year’s edition, factoring in two more years of marijuana sales data in regulated markets. The decision to revise the estimates stems from the high likelihood of Ohio granting voters the opportunity to weigh in on the legalization initiative via the coming ballot.

The outcomes of this research indicate that Ohio could potentially rake in between $276.2 and $403.5 million in annual tax revenue from cannabis sales within five years of its legalization. Notably, the lower estimate remains consistent with the previous year’s report, while the upper range has surged by nearly $30 million due to the inclusion of more sales data from the six states.

This range in estimations results from the utilization of three distinct pricing models. The models map out the potential tax income under the following scenarios: Ohio’s cannabis products are taxed at rates equivalent to Michigan’s, 10% higher or 20% higher.

The paper underscores the pivotal role tax levels and structure would play in determining the final tax revenue. Although the Michigan tax framework and the proposed Ohio tax structure are comparatively modest among legalized states, Ohio could opt for higher taxes, potentially leading to enhanced revenue. Nevertheless, this could inadvertently elevate product costs, making it challenging to combat the illicit marijuana trade and potentially resulting in dwindling tax returns over time.

The report further elucidates that revenue from marijuana tends to exhibit robust growth during the initial stages of adult-use legalization, with a subsequent tapering off as markets mature. As evident from their review of different states, established markets have witnessed declines in cannabis tax revenue, while newer entrants such as Illinois and Michigan experienced significant revenue growth.

The updated analysis projects escalating marijuana revenue in Ohio, projecting figures as high as $218.5 million in the second year of sales, surging to potentially $305.6 million in the third year and $366.8 million in the fourth year. The peak is expected to be reached in the fifth year, hitting the $403.5 million milestone.

Throughout 2023, multiple states with legalized marijuana have reported consistently record-breaking monthly sales. Michigan, for instance, achieved a new monthly record in July, exceeding the previous month’s sales by a substantial margin.

States in the Northeast, including Rhode Island, Massachusetts, Maine and Connecticut, have all marked new records for marijuana transactions. Illinois recorded its strongest sales month to date in July, while Maryland also saw impressive figures since launching its recreational market. Missouri has also experienced a thriving cannabis market since its recreational market initiation in February, boasting daily sales averaging around $4 million and attaining a record-breaking $121.3 million in cannabis purchases in June.

In Ohio, proponents of cannabis legalization are confident about the initiative’s appearance on the ballot. Despite falling short by 679 signatures initially, advocates managed to bridge the gap during a 10-day correction period after submitting a substantial number of petitions. The campaign awaits official confirmation of success from the secretary of state’s office.

Once cannabis is legalized in Ohio, numerous business opportunities are likely to open up for a diverse variety of enterprises, such as Advanced Container Technologies Inc. (OTC: ACTX), which specialize in providing supplies like indoor cultivation equipment to mainstream marijuana companies.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Alternative Products Expo: Pioneering the Counterculture Industry

Counterculture retail professionals, business executives, researchers, and industry leaders, are invited to attend Alternative Products Expo to be held in Las Vegas from September 14-16, 2023.  Dedicated to promoting creativity, the much-awaited event will be focused on eco-friendly solutions and alternative products. The Expo is set to engage audiences with a wide range of unique and sustainable products that signify the latest trends and technological advancements.

The Expo aims to empower participants to make informed buying decisions while contributing to a progressive, more sustainable future. By showcasing a wide range of ethically sourced and environmentally friendly alternatives, the Expo is about creating a socially responsible community that aligns with technological innovations and sustainable best practices.

Alternative Products Expo will feature a diverse group of eco-conscious entrepreneurs, business leaders, and innovators, providing insights into the intricacies of sustainable products while enlightening attendees about market potential and current opportunities.

Innovation meets Sustainability

Alternative Products Expo promises to provide an immersive experience through engaging workshops, enlightening exhibits, and best-in-class networking opportunities. Attendees will get a unique opportunity to meet industry leaders and learn from their experience spanning a range of industries, including renewable energy, vaping, beverages, and more.

Experience the blend of creativity and sustainability as top industry leaders showcase their collections. From fair trade practices to upcycled materials, the Expo will reveal unique, game-changing ideas that drive innovation in style. Business owners will exhibit their newest products, challenging the boundaries and redefining innovation.

Thought-provoking seminars and workshops will enable attendees to learn about the latest innovations in the alternative products industry, from zero-waste packaging to renewable energy solutions.

To learn more, please visit https://cnw.fm/6Dwhq

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Health Insurance Premiums Lower in US Jurisdictions with Medical Marijuana

A recent International Journal of Drug Policy study has found that U.S. states with medical marijuana programs have seen major reductions in health insurance premiums. Compared to states without legal medical marijuana, the study observed that people in states with medical marijuana are paying lower insurance premiums.

Analysis of 10 years’ worth of National Association of Insurance Commissioners private health insurance data revealed that once a state legalized medical marijuana sales, health insurance premiums “dropped dramatically.”

Although the premium reductions were modest after the implementation of medical marijuana laws, yearly health insurance premiums in states with medical marijuana markets fell by $1,663 seven years after implementation, $1,542 eight years later, and $1,626 nine years later.

The researchers noted that although the reduction in health insurance premiums typically did not start until seven years after medical marijuana implementation, states with such programs eventually saw a “significant and sizable reduction” in premiums. The scientists specifically looked at individual private health plans instead of Medicaid or employee-sponsored insurance plans.

In addition, the research team only considered states with medical cannabis markets and excluded any analysis from states with both medical and recreational markets while using states without medical cannabis markets or those that hadn’t implemented already-passed medical cannabis policies as controls. Interestingly, the team found that states which adopted medical marijuana early have seen declines in private health insurance premiums from years three through nine after implementation while mid-adopting states saw an attenuated effect on health insurance premiums after the third year of implementation.

Furthermore, the researchers said that the nature of community rating and insurance pooling made it so that the savings derived from medical marijuana legalizations benefitted both marijuana users and nonusers. Alluding to cannabis reform critics who said legalizing cannabis could potentially result in an increase in healthcare costs, the researchers said that concerns about cannabis reform increasing the burden on healthcare were unfounded.

America’s state-legal cannabis industry now stretches across dozens of states and grants millions of Americans access to medical cannabis. Many people use cannabis as an alternative to pharmaceuticals to treat conditions such as chronic pain, anxiety, and insomnia.

Furthermore, medical marijuana programs allow patients with one or more of more than 20 qualifying conditions to use medical cannabis, often as an alternative to prescription medications. The list cancer, Alzheimer’s disease, anorexia, severe nausea, chronic pain, glaucoma, post-traumatic stress disorder (PTSD), muscle spasms, appetite loss, multiple sclerosis (MS) and HIV/AIDS.

This research depicting reductions in health insurance premiums is testament to the medical potential that marijuana possesses. It is therefore no wonder that companies are focused on developing FDA-grade pharmaceutical formulations from marijuana in order to treat different conditions, such as chronic pain.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Germans Hold Rally Calling for Cannabis Legalization

Demonstrations rocked the German capital city of Berlin last weekend as hundreds of Germans joined the country’s yearly marijuana legalization protests. Held just days before the German country met to discuss the fate of a draft measure that would get rid of Germany’s ban on cannabis, several hundred protestors joined the annual Hanfparade (Hemp Parade) and called on the government to legalize cannabis.

The rally began at the Berlin Rotes Rathaus (Red town hall) before the protestors walked a route that took them through the Unter den Linden boulevard and to the government district.

Held every year since 1997, the Hemp Parade’s main goal is to persuade the government to review and liberalize policies on soft drugs such as hashish and marijuana that come from the marijuana plant. Event organizers also support and advocate for expanded access to medical marijuana as well as the use of hemp, a plant in the cannabis family that produces very minimal amounts of the psychoactive compound tetrahydrocannabinol (THC).

This year’s demonstration motto was “Hemp is great for peace and climate.”

German lawmakers plan on legalizing marijuana and possibly allowing the possession of up to 25 grams of cannabis and home cultivation of up to three cannabis plants for adults. A proposed cannabis legalization law would also allow “cannabis clubs” to cultivate and sell cannabis to adults under specific rules. This includes limiting each customer to 50 grams of cannabis per month and using neutral packaging.

On top of generating millions of dollars in revenue, the proposed law would save Germany’s police force, the legal system and prison facilities more than $1.11 billion in operational costs every year.

Although reform activists hope the bill will advance and finally end cannabis prohibition in Germany, it will likely face plenty of pushback from associated agencies and organizations. For instance, the German Judges Association (DRB) claims upholding the measure will be difficult, calling it a “very small-scale law” that would require a very high degree of control and potentially lead to several court disputes. The DRB added that the legalization measure would have little effect on Germany’s illicit drug market.

German police have also criticized the proposed marijuana legalization measure. Like the DRB, the deputy head of the German Police Union (Gdp) says that the measure “lacks precision and oversight” and will burden the country’s police force to a significant degree. Gdp deputy federal chairman Alexander Poitz argued that the measure does not outline how to source and manage the additional personnel and technical effort law enforcement will need if it becomes law.

The Free Democratic Party (FDP) addiction and drug-policy spokesperson Kristine Lütke also said that the proposal in its current form would “create a bureaucratic monster.”

As more countries consider and implement marijuana legalization measures, many enterprises are likely to mushroom and thrive in the way that companies such as Advanced Container Technologies Inc. (OTC: ACTX) are finding success by doing business with marijuana companies in the U.S.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.